SK1502004A3 - 6,7-Dihydro-5H-pyrazolo[1,2-a] pyrazol-1-ones regulating inflammatory cytokines - Google Patents

6,7-Dihydro-5H-pyrazolo[1,2-a] pyrazol-1-ones regulating inflammatory cytokines Download PDF

Info

Publication number: SK1502004A3
Authority: SK; Slovakia
Prior art keywords: fluorophenyl; dihydro; pyrazolo; pyrazol; substituted
Prior art date: 2001-09-20

Application number

SK150-2004A

Other languages

English (en)

Slovak (sk)

Inventor

Michael Phillip Clark

Matthew John Laufersweiler

Jane Far-Jine Djung

Michael George Natchus

Biswanath De

Original Assignee

Procter & Gamble

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-20

Filing date

2002-09-20

Publication date

2004-09-08

2002-09-20 Application filed by Procter & Gamble filed Critical Procter & Gamble

2004-09-08 Publication of SK1502004A3 publication Critical patent/SK1502004A3/sk

Links

102000004127 Cytokines Human genes 0.000 title claims abstract description 35
108090000695 Cytokines Proteins 0.000 title claims abstract description 35
230000002757 inflammatory effect Effects 0.000 title claims abstract description 23
STKARFFXWORTNB-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical class C1CCN2C(=O)C=CN21 STKARFFXWORTNB-UHFFFAOYSA-N 0.000 title claims description 18
230000001105 regulatory effect Effects 0.000 title claims description 7
239000001257 hydrogen Substances 0.000 claims abstract description 75
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 75
239000000203 mixture Chemical group 0.000 claims abstract description 74
150000001875 compounds Chemical class 0.000 claims abstract description 60
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 39
125000003118 aryl group Chemical group 0.000 claims abstract description 35
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 30
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 25
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 20
125000004429 atom Chemical group 0.000 claims abstract description 18
125000002837 carbocyclic group Chemical group 0.000 claims abstract description 17
150000001412 amines Chemical class 0.000 claims abstract description 11
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 11
150000003839 salts Chemical class 0.000 claims abstract description 9
-1 C 1 -C 4 alkyl Substances 0.000 claims description 448
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 208
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
150000002431 hydrogen Chemical class 0.000 claims description 31
238000000034 method Methods 0.000 claims description 23
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 21
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 12
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 12
125000001183 hydrocarbyl group Chemical group 0.000 claims description 11
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 11
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 10
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 10
239000000546 pharmaceutical excipient Substances 0.000 claims description 10
241000124008 Mammalia Species 0.000 claims description 9
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 8
125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 7
ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims description 7
125000005275 alkylenearyl group Chemical group 0.000 claims description 7
125000005218 alkyleneheteroaryl group Chemical group 0.000 claims description 7
150000001768 cations Chemical class 0.000 claims description 7
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
229910052760 oxygen Inorganic materials 0.000 claims description 7
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 6
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 6
125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims description 6
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 6
229920002554 vinyl polymer Polymers 0.000 claims description 6
229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 claims description 5
XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 claims description 5
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 5
125000001033 ether group Chemical group 0.000 claims description 4
125000003944 tolyl group Chemical group 0.000 claims description 3
QHSCOXHUIJPTPK-UHFFFAOYSA-N 2-(dimethylamino)-6-(4-fluorophenyl)-7-[2-(1-phenylethylamino)pyrimidin-4-yl]-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C=1C=CC=CC=1C(C)NC(N=1)=NC=CC=1C(N1CC(CN1C1=O)N(C)C)=C1C1=CC=C(F)C=C1 QHSCOXHUIJPTPK-UHFFFAOYSA-N 0.000 claims description 2
125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 claims description 2
FIRLRGSIGYHQMD-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-(2-phenoxypyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C1=CC(F)=CC=C1C(C(N1CCCN11)=O)=C1C1=CC=NC(OC=2C=CC=CC=2)=N1 FIRLRGSIGYHQMD-UHFFFAOYSA-N 0.000 claims description 2
WZWVTZQDLHFUSR-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-[2-(2-methoxypropylamino)pyrimidin-4-yl]-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound COC(C)CNC1=NC=CC(C=2N3CCCN3C(=O)C=2C=2C=CC(F)=CC=2)=N1 WZWVTZQDLHFUSR-UHFFFAOYSA-N 0.000 claims description 2
ZQJQDDLGWSLWNG-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-[2-[(3-hydroxy-3-methylbutan-2-yl)amino]pyrimidin-4-yl]-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound CC(O)(C)C(C)NC1=NC=CC(C=2N3CCCN3C(=O)C=2C=2C=CC(F)=CC=2)=N1 ZQJQDDLGWSLWNG-UHFFFAOYSA-N 0.000 claims description 2
UBGIJAMGCVSDSG-UHFFFAOYSA-N 7-[2-(cyclopropylamino)pyrimidin-4-yl]-6-(4-fluorophenyl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C1=CC(F)=CC=C1C(C(N1CCCN11)=O)=C1C1=CC=NC(NC2CC2)=N1 UBGIJAMGCVSDSG-UHFFFAOYSA-N 0.000 claims description 2
WFRORTCUDVWXHF-INIZCTEOSA-N 7-[2-[[(1s)-1-cyclohexylethyl]amino]pyrimidin-4-yl]-6-(4-fluorophenyl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound N([C@@H](C)C1CCCCC1)C(N=1)=NC=CC=1C(N1CCCN1C1=O)=C1C1=CC=C(F)C=C1 WFRORTCUDVWXHF-INIZCTEOSA-N 0.000 claims description 2
241000282412 Homo Species 0.000 claims description 2
WLJVXDMOQOGPHL-UHFFFAOYSA-N benzyl-alpha-carboxylic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 2
229960003424 phenylacetic acid Drugs 0.000 claims description 2
239000003279 phenylacetic acid Substances 0.000 claims description 2
125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 2
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 4
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 4
125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 2
NHGZFNTVAZHJAX-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-[2-(2-methoxyethylamino)pyrimidin-4-yl]-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound COCCNC1=NC=CC(C=2N3CCCN3C(=O)C=2C=2C=CC(F)=CC=2)=N1 NHGZFNTVAZHJAX-UHFFFAOYSA-N 0.000 claims 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
TWWUNSJOKCOGKZ-MRXNPFEDSA-N 6-(4-fluorophenyl)-7-[2-[[(1r)-1-phenylethyl]amino]pyrimidin-4-yl]-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound N([C@H](C)C=1C=CC=CC=1)C(N=1)=NC=CC=1C(N1CCCN1C1=O)=C1C1=CC=C(F)C=C1 TWWUNSJOKCOGKZ-MRXNPFEDSA-N 0.000 claims 1
LSXDMSPDXVTUDM-KRWDZBQOSA-N 6-(4-fluorophenyl)-7-[2-[[(1s)-1-(4-methylphenyl)ethyl]amino]pyrimidin-4-yl]-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound N([C@@H](C)C=1C=CC(C)=CC=1)C(N=1)=NC=CC=1C(N1CCCN1C1=O)=C1C1=CC=C(F)C=C1 LSXDMSPDXVTUDM-KRWDZBQOSA-N 0.000 claims 1
PJEDLKZAMWYCKD-UHFFFAOYSA-N 7-[2-(4-fluorophenoxy)pyrimidin-4-yl]-6-(4-fluorophenyl)-2-morpholin-4-yl-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C1=CC(F)=CC=C1OC1=NC=CC(C=2N3CC(CN3C(=O)C=2C=2C=CC(F)=CC=2)N2CCOCC2)=N1 PJEDLKZAMWYCKD-UHFFFAOYSA-N 0.000 claims 1
ZURAKXYJNNUPSM-UHFFFAOYSA-N 7-[2-(benzylamino)pyrimidin-4-yl]-6-(4-fluorophenyl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C1=CC(F)=CC=C1C(C(N1CCCN11)=O)=C1C1=CC=NC(NCC=2C=CC=CC=2)=N1 ZURAKXYJNNUPSM-UHFFFAOYSA-N 0.000 claims 1
VOUFJXLXOWMZOG-UHFFFAOYSA-N 7-[2-(tert-butylamino)pyrimidin-4-yl]-6-(4-fluorophenyl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound CC(C)(C)NC1=NC=CC(C=2N3CCCN3C(=O)C=2C=2C=CC(F)=CC=2)=N1 VOUFJXLXOWMZOG-UHFFFAOYSA-N 0.000 claims 1
HPXZVRDEUKSFTF-UHFFFAOYSA-N C1CN(S(=O)(=O)CCC)CCC1NC1=NC=CC(C=2N3CCCN3C(=O)C=2C=2C=CC(F)=CC=2)=N1 Chemical compound C1CN(S(=O)(=O)CCC)CCC1NC1=NC=CC(C=2N3CCCN3C(=O)C=2C=2C=CC(F)=CC=2)=N1 HPXZVRDEUKSFTF-UHFFFAOYSA-N 0.000 claims 1
125000001207 fluorophenyl group Chemical group 0.000 claims 1
235000019260 propionic acid Nutrition 0.000 claims 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
150000002170 ethers Chemical class 0.000 abstract description 16
125000004432 carbon atom Chemical group C* 0.000 abstract description 5
229910052799 carbon Inorganic materials 0.000 abstract description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 145
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 122
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 105
239000000243 solution Substances 0.000 description 96
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 72
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 58
238000002360 preparation method Methods 0.000 description 52
235000019439 ethyl acetate Nutrition 0.000 description 51
239000000047 product Substances 0.000 description 50
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
239000003153 chemical reaction reagent Substances 0.000 description 47
239000011541 reaction mixture Substances 0.000 description 39
ZMXDDKWLCZADIW-UHFFFAOYSA-N Vilsmeier-Haack reagent Natural products CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 33
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
239000003921 oil Substances 0.000 description 26
235000019198 oils Nutrition 0.000 description 26
239000012044 organic layer Substances 0.000 description 25
239000007787 solid Substances 0.000 description 25
239000000377 silicon dioxide Substances 0.000 description 24
239000000543 intermediate Substances 0.000 description 22
238000006243 chemical reaction Methods 0.000 description 21
230000000670 limiting effect Effects 0.000 description 21
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
239000010410 layer Substances 0.000 description 18
229920006395 saturated elastomer Polymers 0.000 description 17
201000010099 disease Diseases 0.000 description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
125000003277 amino group Chemical group 0.000 description 15
229910000104 sodium hydride Inorganic materials 0.000 description 15
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
239000000725 suspension Substances 0.000 description 13
239000012267 brine Substances 0.000 description 12
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
238000003756 stirring Methods 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 10
239000000706 filtrate Substances 0.000 description 10
125000005322 morpholin-1-yl group Chemical group 0.000 description 10
239000002904 solvent Substances 0.000 description 10
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
239000012043 crude product Substances 0.000 description 9
239000008346 aqueous phase Substances 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
239000011734 sodium Substances 0.000 description 8
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
102000000589 Interleukin-1 Human genes 0.000 description 7
108010002352 Interleukin-1 Proteins 0.000 description 7
238000001816 cooling Methods 0.000 description 7
239000013058 crude material Substances 0.000 description 7
239000002158 endotoxin Substances 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
238000009472 formulation Methods 0.000 description 6
230000008569 process Effects 0.000 description 6
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
ANGFERNLRQXLRG-UHFFFAOYSA-N benzyl 2-[2-(4-fluorophenyl)acetyl]-4-oxopyrazolidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1CC(=O)N1N(C(=O)OCC=2C=CC=CC=2)CC(=O)C1 ANGFERNLRQXLRG-UHFFFAOYSA-N 0.000 description 5
150000003840 hydrochlorides Chemical class 0.000 description 5
229920006008 lipopolysaccharide Polymers 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
239000000651 prodrug Substances 0.000 description 5
229940002612 prodrug Drugs 0.000 description 5
238000012360 testing method Methods 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 4
ISQQEOJMKNIJEL-UHFFFAOYSA-N 2-phenoxypyrimidine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC(OC=2C=CC=CC=2)=N1 ISQQEOJMKNIJEL-UHFFFAOYSA-N 0.000 description 4
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
229910004373 HOAc Inorganic materials 0.000 description 4
208000022559 Inflammatory bowel disease Diseases 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
CRZQGDNQQAALAY-UHFFFAOYSA-N Methyl benzeneacetate Chemical compound COC(=O)CC1=CC=CC=C1 CRZQGDNQQAALAY-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
BOYHBAGUJONEOG-UHFFFAOYSA-N benzyl 2-[2-(4-fluorophenyl)acetyl]-4-methoxypyrazolidine-1-carboxylate Chemical compound C1C(OC)CN(C(=O)CC=2C=CC(F)=CC=2)N1C(=O)OCC1=CC=CC=C1 BOYHBAGUJONEOG-UHFFFAOYSA-N 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
239000002480 mineral oil Substances 0.000 description 4
235000010446 mineral oil Nutrition 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
238000000746 purification Methods 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
OUBZTWAVXMBDAY-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-(4-morpholin-4-ylpyrazolidin-1-yl)ethanone Chemical compound C1=CC(F)=CC=C1CC(=O)N1NCC(N2CCOCC2)C1 OUBZTWAVXMBDAY-UHFFFAOYSA-N 0.000 description 3
QGJXHPACBLAFFJ-UHFFFAOYSA-N 2-methylsulfanylpyrimidine-4-carbaldehyde Chemical compound CSC1=NC=CC(C=O)=N1 QGJXHPACBLAFFJ-UHFFFAOYSA-N 0.000 description 3
XGAKJVDFGWJLBN-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-(2-methylsulfonylpyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound CS(=O)(=O)C1=NC=CC(C=2N3CCCN3C(=O)C=2C=2C=CC(F)=CC=2)=N1 XGAKJVDFGWJLBN-UHFFFAOYSA-N 0.000 description 3
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
235000019270 ammonium chloride Nutrition 0.000 description 3
ZUTIOUJGTRXZOF-UHFFFAOYSA-N benzyl 2-[2-(4-fluorophenyl)acetyl]-4-hydroxypyrazolidine-1-carboxylate Chemical compound C1C(O)CN(C(=O)CC=2C=CC(F)=CC=2)N1C(=O)OCC1=CC=CC=C1 ZUTIOUJGTRXZOF-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
NWEKLKAEZPSPGG-UHFFFAOYSA-N methyl 2-(4-fluorophenyl)-3-(2-methylsulfanylpyrimidin-4-yl)-3-oxopropanoate Chemical compound C=1C=C(F)C=CC=1C(C(=O)OC)C(=O)C1=CC=NC(SC)=N1 NWEKLKAEZPSPGG-UHFFFAOYSA-N 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
201000008482 osteoarthritis Diseases 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 2
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 2
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
SJXRZXDWZBNBFB-UHFFFAOYSA-N 1-[4-(dimethylamino)-2-(2-methylsulfanylpyrimidine-4-carbonyl)pyrazolidin-1-yl]-2-(4-fluorophenyl)ethanone Chemical compound CSC1=NC=CC(C(=O)N2N(CC(C2)N(C)C)C(=O)CC=2C=CC(F)=CC=2)=N1 SJXRZXDWZBNBFB-UHFFFAOYSA-N 0.000 description 2
JPDCNXBSQDNBDS-UHFFFAOYSA-N 1-[4-(dimethylamino)pyrazolidin-1-yl]-2-(4-fluorophenyl)ethanone Chemical compound C1C(N(C)C)CNN1C(=O)CC1=CC=C(F)C=C1 JPDCNXBSQDNBDS-UHFFFAOYSA-N 0.000 description 2
QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 2
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
MDBJTFHEJIJCRF-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-(4-methoxypyrazolidin-1-yl)ethanone Chemical compound C1C(OC)CNN1C(=O)CC1=CC=C(F)C=C1 MDBJTFHEJIJCRF-UHFFFAOYSA-N 0.000 description 2
VDRSIQZNVUQPBA-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-[4-methoxy-2-(2-methylsulfanylpyrimidine-4-carbonyl)pyrazolidin-1-yl]ethanone Chemical compound C1C(OC)CN(C(=O)CC=2C=CC(F)=CC=2)N1C(=O)C1=CC=NC(SC)=N1 VDRSIQZNVUQPBA-UHFFFAOYSA-N 0.000 description 2
XWWPRCDWMBDLRY-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-[4-morpholin-4-yl-2-(2-phenoxypyrimidine-4-carbonyl)pyrazolidin-1-yl]ethanone Chemical compound C1=CC(F)=CC=C1CC(=O)N1N(C(=O)C=2N=C(OC=3C=CC=CC=3)N=CC=2)CC(N2CCOCC2)C1 XWWPRCDWMBDLRY-UHFFFAOYSA-N 0.000 description 2
SIOJFYRPBYGHOO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetyl chloride Chemical compound FC1=CC=C(CC(Cl)=O)C=C1 SIOJFYRPBYGHOO-UHFFFAOYSA-N 0.000 description 2
HMCVSOQTDRJBTP-UHFFFAOYSA-N 2-(dimethylamino)-6-(4-fluorophenyl)-7-(2-methylsulfanylpyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound CSC1=NC=CC(C=2N3CC(CN3C(=O)C=2C=2C=CC(F)=CC=2)N(C)C)=N1 HMCVSOQTDRJBTP-UHFFFAOYSA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
VXFMVTHYCGTCHL-UHFFFAOYSA-N 2-methylsulfonylpyrimidine-4-carbonyl chloride Chemical compound CS(=O)(=O)C1=NC=CC(C(Cl)=O)=N1 VXFMVTHYCGTCHL-UHFFFAOYSA-N 0.000 description 2
XCQBXQWVOZDGTH-UHFFFAOYSA-N 2-phenoxypyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(OC=2C=CC=CC=2)=N1 XCQBXQWVOZDGTH-UHFFFAOYSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
PZVWKCGKIADPAU-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-ylsulfanyl)aniline Chemical compound C1=CC(N)=CC=C1SC1=NC2=CC=CC=C2S1 PZVWKCGKIADPAU-UHFFFAOYSA-N 0.000 description 2
QYJPLCDXLHEEMF-UHFFFAOYSA-N 4-methylidene-2-[(2-methylpropan-2-yl)oxycarbonyl]pyrazolidine-1-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)N1N(CC(C1)=C)C(=O)O QYJPLCDXLHEEMF-UHFFFAOYSA-N 0.000 description 2
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
AKLKEMALKIMWBQ-UHFFFAOYSA-N 6-(4-fluorophenyl)-2-hydroxy-7-(2-phenoxypyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound O=C1N2CC(O)CN2C(C=2N=C(OC=3C=CC=CC=3)N=CC=2)=C1C1=CC=C(F)C=C1 AKLKEMALKIMWBQ-UHFFFAOYSA-N 0.000 description 2
NAZQNCBXFCUNEG-UHFFFAOYSA-N 6-(4-fluorophenyl)-2-methoxy-7-(2-methylsulfonylpyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound O=C1N2CC(OC)CN2C(C=2N=C(N=CC=2)S(C)(=O)=O)=C1C1=CC=C(F)C=C1 NAZQNCBXFCUNEG-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
206010006895 Cachexia Diseases 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
102000004889 Interleukin-6 Human genes 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
102000004890 Interleukin-8 Human genes 0.000 description 2
108090001007 Interleukin-8 Proteins 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
239000012425 OXONE® Substances 0.000 description 2
235000019502 Orange oil Nutrition 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
KWKIFBQOGUTVBO-UHFFFAOYSA-N [1-[2-(4-fluorophenyl)acetyl]-2-(2-methylsulfanylpyrimidine-4-carbonyl)pyrazolidin-4-yl] 2,2-dimethylpropanoate Chemical compound CSC1=NC=CC(C(=O)N2N(CC(C2)OC(=O)C(C)(C)C)C(=O)CC=2C=CC(F)=CC=2)=N1 KWKIFBQOGUTVBO-UHFFFAOYSA-N 0.000 description 2
HVJGDUTWIXHXAD-UHFFFAOYSA-N [1-[2-(4-fluorophenyl)acetyl]-2-(2-phenoxypyrimidine-4-carbonyl)pyrazolidin-4-yl] morpholine-4-carboxylate Chemical compound C1=CC(F)=CC=C1CC(=O)N1N(C(=O)C=2N=C(OC=3C=CC=CC=3)N=CC=2)CC(OC(=O)N2CCOCC2)C1 HVJGDUTWIXHXAD-UHFFFAOYSA-N 0.000 description 2
ANEDSOHLDQAVDN-UHFFFAOYSA-N [1-[2-(4-fluorophenyl)acetyl]-2-phenylmethoxycarbonylpyrazolidin-4-yl] morpholine-4-carboxylate Chemical compound C1=CC(F)=CC=C1CC(=O)N1N(C(=O)OCC=2C=CC=CC=2)CC(OC(=O)N2CCOCC2)C1 ANEDSOHLDQAVDN-UHFFFAOYSA-N 0.000 description 2
YKMWXHIIAAXJLV-UHFFFAOYSA-N [1-[2-(4-fluorophenyl)acetyl]pyrazolidin-4-yl] 2,2-dimethylpropanoate Chemical compound C1C(OC(=O)C(C)(C)C)CNN1C(=O)CC1=CC=C(F)C=C1 YKMWXHIIAAXJLV-UHFFFAOYSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
FIVIYCCIEIIOSA-UHFFFAOYSA-N benzyl 2-[2-(4-fluorophenyl)acetyl]-4-(4-nitrophenoxy)carbonyloxypyrazolidine-1-carboxylate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1CN(C(=O)OCC=2C=CC=CC=2)N(C(=O)CC=2C=CC(F)=CC=2)C1 FIVIYCCIEIIOSA-UHFFFAOYSA-N 0.000 description 2
FLZJCIJETJDKHZ-UHFFFAOYSA-N benzyl 2-[2-(4-fluorophenyl)acetyl]-4-methylidenepyrazolidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1CC(=O)N1N(C(=O)OCC=2C=CC=CC=2)CC(=C)C1 FLZJCIJETJDKHZ-UHFFFAOYSA-N 0.000 description 2
XXIWUZKNXKXZBD-UHFFFAOYSA-N benzyl 4-(2,2-dimethylpropanoyloxy)-2-[2-(4-fluorophenyl)acetyl]pyrazolidine-1-carboxylate Chemical compound C1C(OC(=O)C(C)(C)C)CN(C(=O)CC=2C=CC(F)=CC=2)N1C(=O)OCC1=CC=CC=C1 XXIWUZKNXKXZBD-UHFFFAOYSA-N 0.000 description 2
IGIDKOAZDRYLKI-UHFFFAOYSA-N benzyl 4-(dimethylamino)-2-[2-(4-fluorophenyl)acetyl]pyrazolidine-1-carboxylate Chemical compound C1C(N(C)C)CN(C(=O)CC=2C=CC(F)=CC=2)N1C(=O)OCC1=CC=CC=C1 IGIDKOAZDRYLKI-UHFFFAOYSA-N 0.000 description 2
ZXPWSWRNPBDBGH-UHFFFAOYSA-N benzyl 4-methylidenepyrazolidine-1-carboxylate Chemical compound C1C(=C)CNN1C(=O)OCC1=CC=CC=C1 ZXPWSWRNPBDBGH-UHFFFAOYSA-N 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
230000002612 cardiopulmonary effect Effects 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
238000001952 enzyme assay Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
125000001041 indolyl group Chemical group 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
229940100601 interleukin-6 Drugs 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
FJESTSZQODSANC-UHFFFAOYSA-N methyl 2-(4-fluorophenyl)-3-hydroxy-3-(2-methylsulfanylpyrimidin-4-yl)propanoate Chemical compound C=1C=C(F)C=CC=1C(C(=O)OC)C(O)C1=CC=NC(SC)=N1 FJESTSZQODSANC-UHFFFAOYSA-N 0.000 description 2
GMEBDKGPPKAPEM-UHFFFAOYSA-N methyl 2-[3-(trifluoromethyl)phenyl]acetate Chemical compound COC(=O)CC1=CC=CC(C(F)(F)F)=C1 GMEBDKGPPKAPEM-UHFFFAOYSA-N 0.000 description 2
NWDADIBYIHDSHF-UHFFFAOYSA-N methyl 2-methylsulfonylpyrimidine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(S(C)(=O)=O)=N1 NWDADIBYIHDSHF-UHFFFAOYSA-N 0.000 description 2
ONLQTQQQTMANMX-UHFFFAOYSA-N methyl 2-phenoxypyrimidine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(OC=2C=CC=CC=2)=N1 ONLQTQQQTMANMX-UHFFFAOYSA-N 0.000 description 2
125000006431 methyl cyclopropyl group Chemical group 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 description 2
125000002757 morpholinyl group Chemical group 0.000 description 2
239000010502 orange oil Substances 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 2
238000002953 preparative HPLC Methods 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
229910001923 silver oxide Inorganic materials 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
NXMXETCTWNXSFG-BYPYZUCNSA-N (2s)-1-methoxypropan-2-amine Chemical compound COC[C@H](C)N NXMXETCTWNXSFG-BYPYZUCNSA-N 0.000 description 1
VFNVJVXCTYVZEU-ZBHICJROSA-N (2s)-2-amino-3-methylpentan-3-ol Chemical compound CCC(C)(O)[C@H](C)N VFNVJVXCTYVZEU-ZBHICJROSA-N 0.000 description 1
OVKDLPZRDQTOJW-BYPYZUCNSA-N (3s)-3-amino-2-methylbutan-2-ol Chemical compound C[C@H](N)C(C)(C)O OVKDLPZRDQTOJW-BYPYZUCNSA-N 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
SCFGHDIKKZVWMU-UHFFFAOYSA-N 1-o-benzyl 2-o-tert-butyl 4-(2,2-dimethylpropanoyloxy)pyrazolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CC(OC(=O)C(C)(C)C)CN1C(=O)OCC1=CC=CC=C1 SCFGHDIKKZVWMU-UHFFFAOYSA-N 0.000 description 1
JFBLEDVRFCFEQA-UHFFFAOYSA-N 1-o-benzyl 2-o-tert-butyl 4-hydroxypyrazolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CC(O)CN1C(=O)OCC1=CC=CC=C1 JFBLEDVRFCFEQA-UHFFFAOYSA-N 0.000 description 1
RGFRKPOBAVBBCN-UHFFFAOYSA-N 1-o-benzyl 2-o-tert-butyl 4-methoxypyrazolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CC(OC)CN1C(=O)OCC1=CC=CC=C1 RGFRKPOBAVBBCN-UHFFFAOYSA-N 0.000 description 1
ZIBBYQDOFMVSTR-UHFFFAOYSA-N 1-o-benzyl 2-o-tert-butyl 4-methylidenepyrazolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=C)CN1C(=O)OCC1=CC=CC=C1 ZIBBYQDOFMVSTR-UHFFFAOYSA-N 0.000 description 1
GJHJDXWVXVNIET-UHFFFAOYSA-N 1-o-benzyl 2-o-tert-butyl 4-oxopyrazolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)CN1C(=O)OCC1=CC=CC=C1 GJHJDXWVXVNIET-UHFFFAOYSA-N 0.000 description 1
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 1
XIZPKYDUWWYMTJ-UHFFFAOYSA-N 2-(dimethylamino)-6-(4-fluorophenyl)-7-(2-methylsulfonylpyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound O=C1N2CC(N(C)C)CN2C(C=2N=C(N=CC=2)S(C)(=O)=O)=C1C1=CC=C(F)C=C1 XIZPKYDUWWYMTJ-UHFFFAOYSA-N 0.000 description 1
QHSCOXHUIJPTPK-PBVYKCSPSA-N 2-(dimethylamino)-6-(4-fluorophenyl)-7-[2-[[(1s)-1-phenylethyl]amino]pyrimidin-4-yl]-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(N=1)=NC=CC=1C(N1CC(CN1C1=O)N(C)C)=C1C1=CC=C(F)C=C1 QHSCOXHUIJPTPK-PBVYKCSPSA-N 0.000 description 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
XJFZOSUFGSANIF-UHFFFAOYSA-N 3-chloro-2-(chloromethyl)prop-1-ene Chemical compound ClCC(=C)CCl XJFZOSUFGSANIF-UHFFFAOYSA-N 0.000 description 1
ZZIXNGRDILYTIK-UHFFFAOYSA-N 3-methylpyrazolidine Chemical compound CC1CCNN1 ZZIXNGRDILYTIK-UHFFFAOYSA-N 0.000 description 1
VBBKWKZVXOBCLB-UHFFFAOYSA-N 4-(2,2-dimethylpropanoyloxy)pyrazolidine-1-carboxylic acid Chemical compound CC(C)(C)C(=O)OC1CNN(C(O)=O)C1 VBBKWKZVXOBCLB-UHFFFAOYSA-N 0.000 description 1
PTYFBMBIEDVSIA-UHFFFAOYSA-N 4-(dimethoxymethyl)-2-methylsulfanylpyrimidine Chemical compound COC(OC)C1=CC=NC(SC)=N1 PTYFBMBIEDVSIA-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
WGZYVHFXLPDNDL-UHFFFAOYSA-N 4-benzoyl-2-phenylpyrazole-3-carbonitrile Chemical compound C=1C=CC=CC=1C(=O)C(=C1C#N)C=NN1C1=CC=CC=C1 WGZYVHFXLPDNDL-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
XEWCMDOEWDHKKQ-UHFFFAOYSA-N 4-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonyl]pyrazolidine-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC(O)CN1C(O)=O XEWCMDOEWDHKKQ-UHFFFAOYSA-N 0.000 description 1
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
KFCDYUWYCACZLV-UHFFFAOYSA-N 6-(2,4-difluorophenyl)-7-(2-phenoxypyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound FC1=CC(F)=CC=C1C(C(N1CCCN11)=O)=C1C1=CC=NC(OC=2C=CC=CC=2)=N1 KFCDYUWYCACZLV-UHFFFAOYSA-N 0.000 description 1
VGBFBXCSYKHNOT-UHFFFAOYSA-N 6-(4-fluorophenyl)-2-methoxy-7-(2-methylsulfanylpyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound O=C1N2CC(OC)CN2C(C=2N=C(SC)N=CC=2)=C1C1=CC=C(F)C=C1 VGBFBXCSYKHNOT-UHFFFAOYSA-N 0.000 description 1
VCJHBXFRCIQLER-UHFFFAOYSA-N 6-(4-fluorophenyl)-2-morpholin-4-yl-7-(2-phenoxypyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C1=CC(F)=CC=C1C(C(N1CC(CN11)N2CCOCC2)=O)=C1C1=CC=NC(OC=2C=CC=CC=2)=N1 VCJHBXFRCIQLER-UHFFFAOYSA-N 0.000 description 1
UWWFWMBQAWGKCN-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-(2-methylsulfanylpyrimidin-4-yl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound CSC1=NC=CC(C=2N3CCCN3C(=O)C=2C=2C=CC(F)=CC=2)=N1 UWWFWMBQAWGKCN-UHFFFAOYSA-N 0.000 description 1
LFNXXYAEMHVLBI-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-[2-(1,3,4-thiadiazol-2-ylamino)pyrimidin-4-yl]-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C1=CC(F)=CC=C1C(C(N1CCCN11)=O)=C1C1=CC=NC(NC=2SC=NN=2)=N1 LFNXXYAEMHVLBI-UHFFFAOYSA-N 0.000 description 1
HLPJRLLPIGPREM-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-[2-(2-methyl-2-phenylhydrazinyl)pyrimidin-4-yl]-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C=1C=CC=CC=1N(C)NC(N=1)=NC=CC=1C(N1CCCN1C1=O)=C1C1=CC=C(F)C=C1 HLPJRLLPIGPREM-UHFFFAOYSA-N 0.000 description 1
SNDBUJQBPYPQKG-UHFFFAOYSA-N 6-(4-fluorophenyl)-7-[2-[2-[(4-methoxyphenyl)methyl]hydrazinyl]pyrimidin-4-yl]-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C1=CC(OC)=CC=C1CNNC1=NC=CC(C=2N3CCCN3C(=O)C=2C=2C=CC(F)=CC=2)=N1 SNDBUJQBPYPQKG-UHFFFAOYSA-N 0.000 description 1
UKLWIHFHMHQYMR-HNNXBMFYSA-N 6-(4-fluorophenyl)-7-[2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]pyrimidin-4-yl]-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=NC=CC=1C(N1CCCN1C1=O)=C1C1=CC=C(F)C=C1 UKLWIHFHMHQYMR-HNNXBMFYSA-N 0.000 description 1
ZNLVBAMGIQLHLC-UHFFFAOYSA-N 7-[2-(6-aminopyrimidin-4-yl)oxypyrimidin-4-yl]-6-(4-fluorophenyl)-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-5-one Chemical compound C1=NC(N)=CC(OC=2N=C(C=CN=2)C=2N3CCCN3C(=O)C=2C=2C=CC(F)=CC=2)=N1 ZNLVBAMGIQLHLC-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
ZTVALWHZGXUFAP-UHFFFAOYSA-N CC(C)(C)C(=O)OC1CN(N(C1)C(=O)OC(C)(C)C)C(=O)O Chemical compound CC(C)(C)C(=O)OC1CN(N(C1)C(=O)OC(C)(C)C)C(=O)O ZTVALWHZGXUFAP-UHFFFAOYSA-N 0.000 description 1
JOVVVLJFLFTTIM-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C(CCN1C(=O)O)OC Chemical compound CC(C)(C)OC(=O)N1C(CCN1C(=O)O)OC JOVVVLJFLFTTIM-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
JKFMTCOZPDABJG-UHFFFAOYSA-N [1-[2-(4-fluorophenyl)acetyl]pyrazolidin-4-yl] morpholine-4-carboxylate Chemical compound C1=CC(F)=CC=C1CC(=O)N1NCC(OC(=O)N2CCOCC2)C1 JKFMTCOZPDABJG-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012223 aqueous fraction Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
125000002785 azepinyl group Chemical group 0.000 description 1
125000003828 azulenyl group Chemical group 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
YICJZRMFELYBLK-UHFFFAOYSA-N benzyl 2-[2-(4-fluorophenyl)acetyl]-4-morpholin-4-ylpyrazolidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1CC(=O)N1N(C(=O)OCC=2C=CC=CC=2)CC(N2CCOCC2)C1 YICJZRMFELYBLK-UHFFFAOYSA-N 0.000 description 1
UYUGVAGKAKJIOZ-UHFFFAOYSA-N benzyl 4-(2,2-dimethylpropanoyloxy)pyrazolidine-1-carboxylate Chemical compound C1C(OC(=O)C(C)(C)C)CNN1C(=O)OCC1=CC=CC=C1 UYUGVAGKAKJIOZ-UHFFFAOYSA-N 0.000 description 1
SBXLAJWMWLOZET-UHFFFAOYSA-N benzyl n-[(2-methylpropan-2-yl)oxycarbonylamino]carbamate Chemical compound CC(C)(C)OC(=O)NNC(=O)OCC1=CC=CC=C1 SBXLAJWMWLOZET-UHFFFAOYSA-N 0.000 description 1
125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000010779 crude oil Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
125000003700 epoxy group Chemical group 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
239000006260 foam Substances 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
102000057041 human TNF Human genes 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
AJPPKGMEHMXPMC-UHFFFAOYSA-N methyl 2-(4-fluorophenyl)acetate Chemical compound COC(=O)CC1=CC=C(F)C=C1 AJPPKGMEHMXPMC-UHFFFAOYSA-N 0.000 description 1
IOWBEZLBCKONCE-UHFFFAOYSA-N methyl 2-methylsulfanylpyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(SC)=C1 IOWBEZLBCKONCE-UHFFFAOYSA-N 0.000 description 1
IDXMZCVTPNXTBD-UHFFFAOYSA-N methyl 2-methylsulfanylpyrimidine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(SC)=N1 IDXMZCVTPNXTBD-UHFFFAOYSA-N 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
NHANUAJDZLJCMR-UHFFFAOYSA-N n-[3-[4-[6-(4-fluorophenyl)-5-oxo-2,3-dihydro-1h-pyrazolo[1,2-a]pyrazol-7-yl]pyrimidin-2-yl]oxyphenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(OC=2N=C(C=CN=2)C=2N3CCCN3C(=O)C=2C=2C=CC(F)=CC=2)=C1 NHANUAJDZLJCMR-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000007302 negative regulation of cytokine production Effects 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000003585 oxepinyl group Chemical group 0.000 description 1
125000005646 oximino group Chemical group 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
125000005561 phenanthryl group Chemical group 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000001422 pyrrolinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
150000003335 secondary amines Chemical group 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
NESLWCLHZZISNB-UHFFFAOYSA-M sodium phenolate Chemical compound [Na+].[O-]C1=CC=CC=C1 NESLWCLHZZISNB-UHFFFAOYSA-M 0.000 description 1
GRONZTPUWOOUFQ-UHFFFAOYSA-M sodium;methanol;hydroxide Chemical compound [OH-].[Na+].OC GRONZTPUWOOUFQ-UHFFFAOYSA-M 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
230000008354 tissue degradation Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

SK150-2004A 2001-09-20 2002-09-20 6,7-Dihydro-5H-pyrazolo[1,2-a] pyrazol-1-ones regulating inflammatory cytokines SK1502004A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32362501P	2001-09-20	2001-09-20
PCT/US2002/030135 WO2003024971A1 (en)	2001-09-20	2002-09-20	6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Publications (1)

Publication Number	Publication Date
SK1502004A3 true SK1502004A3 (en)	2004-09-08

Family

ID=23259997

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SK150-2004A SK1502004A3 (en)	2001-09-20	2002-09-20	6,7-Dihydro-5H-pyrazolo[1,2-a] pyrazol-1-ones regulating inflammatory cytokines
SK148-2004A SK1482004A3 (en)	2001-09-20	2002-09-20	Compounds which inhibit the release of inflammatory cytokines
SK149-2004A SK1492004A3 (en)	2001-09-20	2002-09-20	Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SK148-2004A SK1482004A3 (en)	2001-09-20	2002-09-20	Compounds which inhibit the release of inflammatory cytokines
SK149-2004A SK1492004A3 (en)	2001-09-20	2002-09-20	Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Country Status (32)

Country	Link
US (2)	US6821971B2 (es)
EP (3)	EP1427727B1 (es)
JP (3)	JP2005504082A (es)
KR (4)	KR20060036125A (es)
CN (3)	CN1257905C (es)
AR (3)	AR037145A1 (es)
AT (3)	ATE287887T1 (es)
AU (2)	AU2002327690B2 (es)
BR (3)	BR0212716A (es)
CA (3)	CA2461071A1 (es)
CO (3)	CO5560590A2 (es)
CY (1)	CY1106398T1 (es)
CZ (3)	CZ2004361A3 (es)
DE (3)	DE60213108T2 (es)
DK (2)	DK1427732T3 (es)
EG (2)	EG24413A (es)
ES (3)	ES2282459T3 (es)
HU (3)	HUP0402378A3 (es)
IL (3)	IL160682A0 (es)
MA (3)	MA27064A1 (es)
MX (3)	MXPA04002569A (es)
MY (2)	MY129329A (es)
NO (2)	NO20041594L (es)
NZ (3)	NZ531123A (es)
PE (3)	PE20030474A1 (es)
PL (3)	PL370362A1 (es)
PT (3)	PT1427727E (es)
RU (3)	RU2278864C2 (es)
SA (1)	SA03230529B1 (es)
SK (3)	SK1502004A3 (es)
WO (3)	WO2003024973A1 (es)
ZA (3)	ZA200401260B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6849627B2 (en)	2001-09-20	2005-02-01	The Procter & Gamble Company	6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US6730668B2 (en) *	2001-09-20	2004-05-04	The Procter & Gamble Company	6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7087615B2 (en)	2001-09-20	2006-08-08	The Procter & Gamble Company	6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia
US7473695B2 (en) *	2001-10-22	2009-01-06	Mitsubishi Tanabe Pharma Corporation	4-imidazolin-2-one compounds
US6677337B2 (en) *	2002-03-19	2004-01-13	The Procter & Gamble Company	1,2-dihydropyrazol-3-ones which controls inflammatory cytokines
PL379544A1 (pl) *	2002-09-09	2006-10-02	Amgen Inc.	1,4,5-podstawione pochodne 1,2-dihydro-pirazol-3-onu i 3-alkoksy 1H-pirazolu jako środki obniżające poziom TNF-alfa oraz interleukin do leczenia stanów zapalnych
WO2004087696A1 (de) *	2003-04-03	2004-10-14	Merck Patent Gmbh	Pirazolidin-1,2-dicarbonsaüre-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
GB0308466D0 (en) *	2003-04-11	2003-05-21	Novartis Ag	Organic compounds
US7482356B2 (en) *	2003-11-10	2009-01-27	The Procter & Gamble Company	Bicyclic pyrazolone cytokine inhibitors
EP2012778A4 (en) *	2006-04-18	2011-08-10	Abbott Lab	VANILLOID RECEPTOR (VR1) SUBType 1 ANTAGONISTS AND USES THEREOF
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
MX2011012343A (es) *	2009-05-19	2011-12-14	Dow Agrosciences Llc	Compuestos y metodos para controlar hongos.
WO2016205284A1 (en)	2015-06-15	2016-12-22	Cummins Inc.	Combustion chamber elasticity device
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
CN107033090B (zh) *	2017-05-16	2019-05-07	无锡捷化医药科技有限公司	一种1,2,3,4-四氢噌啉的制备方法
RU2721684C1 (ru) *	2019-09-06	2020-05-21	Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет"	Метил 2,3,8-триоксо-4-фенилтетрагидро-6Н-пиразоло[1,2-а]пирроло[2,3-c]пиразол-9а(1Н)-карбоксилаты
EP4422621A4 (en) *	2021-10-27	2025-08-27	Merck Sharp & Dohme Llc	SPIROTRICYCLIC RIPK1 INHIBITORS AND METHODS OF USE THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1054291A (es)	1963-02-26
GB1124982A (en) *	1965-02-09	1968-08-21	Lepetit Spa	Diazabicyclo octanes and derivatives thereof
CH529153A (fr)	1969-10-27	1972-10-15	Lepetit Spa	Procédé de préparation de pyrazolo (1,2-b) phtalazine-1,5 (10H)-diones
US5358924A (en) *	1991-03-21	1994-10-25	Bayer Aktiengesellschaft	3-hydroxy-4-aryl-5-oxo-pyrozoline derivatives, compositions and use
DK0640086T3 (da) *	1992-05-15	1999-12-06	Merrell Pharma Inc	Mercaptoacetylamido-pyridazo[1,2-a][1,2]diazepin-derivateranvendelige som enkephalinase- og ACE-inhibitorer
GB9303993D0 (en) *	1993-02-26	1993-04-14	Fujisawa Pharmaceutical Co	New heterocyclic derivatives
CN1272324C (zh) *	1999-09-07	2006-08-30	辛根塔参与股份公司	新颖的除草剂
US6730668B2 (en) *	2001-09-20	2004-05-04	The Procter & Gamble Company	6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

2002
- 2002-09-18 US US10/245,927 patent/US6821971B2/en not_active Expired - Fee Related
- 2002-09-18 US US10/246,499 patent/US6566357B1/en not_active Expired - Fee Related
- 2002-09-20 CA CA002461071A patent/CA2461071A1/en not_active Abandoned
- 2002-09-20 DE DE60213108T patent/DE60213108T2/de not_active Expired - Fee Related
- 2002-09-20 AT AT02763692T patent/ATE287887T1/de not_active IP Right Cessation
- 2002-09-20 CN CNB028182286A patent/CN1257905C/zh not_active Expired - Fee Related
- 2002-09-20 AU AU2002327690A patent/AU2002327690B2/en not_active Ceased
- 2002-09-20 MX MXPA04002569A patent/MXPA04002569A/es active IP Right Grant
- 2002-09-20 EP EP02763692A patent/EP1427727B1/en not_active Expired - Lifetime
- 2002-09-20 PE PE2002000925A patent/PE20030474A1/es not_active Application Discontinuation
- 2002-09-20 CZ CZ2004361A patent/CZ2004361A3/cs unknown
- 2002-09-20 PT PT02763692T patent/PT1427727E/pt unknown
- 2002-09-20 RU RU2004111805/04A patent/RU2278864C2/ru active
- 2002-09-20 CN CNB028183800A patent/CN1249066C/zh not_active Expired - Fee Related
- 2002-09-20 EP EP02763693A patent/EP1427728B1/en not_active Expired - Lifetime
- 2002-09-20 JP JP2003528818A patent/JP2005504082A/ja active Pending
- 2002-09-20 IL IL16068202A patent/IL160682A0/xx unknown
- 2002-09-20 CA CA002461073A patent/CA2461073A1/en not_active Abandoned
- 2002-09-20 ES ES02763693T patent/ES2282459T3/es not_active Expired - Lifetime
- 2002-09-20 PT PT02763693T patent/PT1427728E/pt unknown
- 2002-09-20 AR ARP020103548A patent/AR037145A1/es unknown
- 2002-09-20 KR KR1020067006983A patent/KR20060036125A/ko not_active Ceased
- 2002-09-20 MY MYPI20023518A patent/MY129329A/en unknown
- 2002-09-20 JP JP2003528820A patent/JP2005504083A/ja active Pending
- 2002-09-20 PL PL02370362A patent/PL370362A1/xx not_active Application Discontinuation
- 2002-09-20 DE DE60218704T patent/DE60218704T2/de not_active Expired - Lifetime
- 2002-09-20 SK SK150-2004A patent/SK1502004A3/sk unknown
- 2002-09-20 CA CA002461072A patent/CA2461072A1/en not_active Abandoned
- 2002-09-20 ES ES02763692T patent/ES2237691T3/es not_active Expired - Lifetime
- 2002-09-20 HU HU0402378A patent/HUP0402378A3/hu unknown
- 2002-09-20 CN CNB028182294A patent/CN1250551C/zh not_active Expired - Fee Related
- 2002-09-20 DE DE60202782T patent/DE60202782T2/de not_active Expired - Lifetime
- 2002-09-20 PE PE2002000924A patent/PE20030446A1/es not_active Application Discontinuation
- 2002-09-20 CZ CZ2004345A patent/CZ2004345A3/cs unknown
- 2002-09-20 PL PL02370415A patent/PL370415A1/xx not_active Application Discontinuation
- 2002-09-20 WO PCT/US2002/030133 patent/WO2003024973A1/en not_active Ceased
- 2002-09-20 RU RU2004111803/04A patent/RU2299885C2/ru active
- 2002-09-20 HU HU0402500A patent/HUP0402500A3/hu unknown
- 2002-09-20 KR KR1020047004045A patent/KR100623879B1/ko not_active Expired - Fee Related
- 2002-09-20 EP EP02799017A patent/EP1427732B1/en not_active Expired - Lifetime
- 2002-09-20 AT AT02763693T patent/ATE356126T1/de not_active IP Right Cessation
- 2002-09-20 WO PCT/US2002/030135 patent/WO2003024971A1/en not_active Ceased
- 2002-09-20 PE PE2002000923A patent/PE20030430A1/es not_active Application Discontinuation
- 2002-09-20 SK SK148-2004A patent/SK1482004A3/sk unknown
- 2002-09-20 BR BR0212716-4A patent/BR0212716A/pt not_active IP Right Cessation
- 2002-09-20 AR ARP020103549A patent/AR037502A1/es not_active Application Discontinuation
- 2002-09-20 DK DK02799017T patent/DK1427732T3/da active
- 2002-09-20 SK SK149-2004A patent/SK1492004A3/sk unknown
- 2002-09-20 JP JP2003528817A patent/JP2005504081A/ja active Pending
- 2002-09-20 PT PT02799017T patent/PT1427732E/pt unknown
- 2002-09-20 BR BR0212905-1A patent/BR0212905A/pt not_active IP Right Cessation
- 2002-09-20 NZ NZ531123A patent/NZ531123A/en not_active IP Right Cessation
- 2002-09-20 IL IL16074102A patent/IL160741A0/xx unknown
- 2002-09-20 CZ CZ2004358A patent/CZ2004358A3/cs unknown
- 2002-09-20 RU RU2004111806/04A patent/RU2272040C2/ru not_active IP Right Cessation
- 2002-09-20 KR KR1020047004043A patent/KR100656126B1/ko not_active Expired - Fee Related
- 2002-09-20 WO PCT/US2002/030134 patent/WO2003024970A1/en not_active Ceased
- 2002-09-20 AU AU2002334641A patent/AU2002334641B2/en not_active Expired - Fee Related
- 2002-09-20 NZ NZ531122A patent/NZ531122A/en unknown
- 2002-09-20 MX MXPA04002574A patent/MXPA04002574A/es active IP Right Grant
- 2002-09-20 AT AT02799017T patent/ATE332901T1/de not_active IP Right Cessation
- 2002-09-20 MX MXPA04002570A patent/MXPA04002570A/es active IP Right Grant
- 2002-09-20 ES ES02799017T patent/ES2268154T3/es not_active Expired - Lifetime
- 2002-09-20 KR KR10-2004-7004046A patent/KR20040035837A/ko not_active Ceased
- 2002-09-20 BR BR0212673-7A patent/BR0212673A/pt not_active IP Right Cessation
- 2002-09-20 HU HU0500752A patent/HUP0500752A2/hu unknown
- 2002-09-20 DK DK02763693T patent/DK1427728T3/da active
- 2002-09-20 AR ARP020103550A patent/AR037237A1/es not_active Application Discontinuation
- 2002-09-20 MY MYPI20023502A patent/MY129069A/en unknown
- 2002-09-20 PL PL02370351A patent/PL370351A1/xx not_active Application Discontinuation
- 2002-09-20 NZ NZ531063A patent/NZ531063A/en not_active IP Right Cessation
- 2002-09-20 IL IL16074202A patent/IL160742A0/xx unknown
- 2002-09-21 EG EG2002091039A patent/EG24413A/xx active
- 2002-09-21 EG EG2002091037A patent/EG24363A/xx active
2003
- 2003-01-26 SA SA3230529A patent/SA03230529B1/ar unknown
2004
- 2004-02-17 ZA ZA200401260A patent/ZA200401260B/en unknown
- 2004-02-20 ZA ZA200401402A patent/ZA200401402B/en unknown
- 2004-02-20 ZA ZA200401403A patent/ZA200401403B/en unknown
- 2004-03-09 CO CO04021425A patent/CO5560590A2/es not_active Application Discontinuation
- 2004-03-09 CO CO04021424A patent/CO5560589A2/es not_active Application Discontinuation
- 2004-03-10 MA MA27567A patent/MA27064A1/fr unknown
- 2004-03-10 MA MA27568A patent/MA27065A1/fr unknown
- 2004-03-10 MA MA27569A patent/MA27066A1/fr unknown
- 2004-03-12 CO CO04023010A patent/CO5560579A2/es not_active Application Discontinuation
- 2004-04-19 NO NO20041594A patent/NO20041594L/no not_active Application Discontinuation
- 2004-04-20 NO NO20041605A patent/NO20041605L/no not_active Application Discontinuation
2007
- 2007-03-20 CY CY20071100383T patent/CY1106398T1/el unknown

Also Published As

Publication number	Publication date
NZ531122A (en)	2005-09-30
CN1250551C (zh)	2006-04-12
CN1257905C (zh)	2006-05-31
EP1427732A1 (en)	2004-06-16
MXPA04002570A (es)	2004-05-31
CN1556811A (zh)	2004-12-22
KR100656126B1 (ko)	2006-12-12
PL370415A1 (en)	2005-05-30
AU2002327690B2 (en)	2006-07-20
WO2003024970A1 (en)	2003-03-27
MA27066A1 (fr)	2004-12-20
JP2005504081A (ja)	2005-02-10
ZA200401260B (en)	2004-08-30
EP1427732B1 (en)	2006-07-12
EP1427727B1 (en)	2005-01-26
PT1427732E (pt)	2006-12-29
ATE287887T1 (de)	2005-02-15
EG24363A (en)	2009-03-04
BR0212716A (pt)	2004-08-03
SK1492004A3 (en)	2004-11-03
BR0212905A (pt)	2004-10-13
HUP0402500A2 (hu)	2005-03-29
KR100623879B1 (ko)	2006-09-19
ES2282459T3 (es)	2007-10-16
DK1427728T3 (da)	2007-07-09
CZ2004361A3 (cs)	2004-07-14
ES2268154T3 (es)	2007-03-16
PE20030474A1 (es)	2003-07-22
US6821971B2 (en)	2004-11-23
PT1427728E (pt)	2007-05-31
ZA200401403B (en)	2004-08-30
HUP0402378A2 (hu)	2005-02-28
KR20060036125A (ko)	2006-04-27
RU2004111805A (ru)	2005-04-10
RU2004111806A (ru)	2005-03-27
DE60218704T2 (de)	2007-11-08
HUP0402500A3 (en)	2008-10-28
HK1071366A1 (en)	2005-07-15
IL160742A0 (en)	2004-08-31
EP1427727A1 (en)	2004-06-16
RU2299885C2 (ru)	2007-05-27
CN1555375A (zh)	2004-12-15
RU2272040C2 (ru)	2006-03-20
CY1106398T1 (el)	2011-10-12
KR20040035837A (ko)	2004-04-29
KR20040035836A (ko)	2004-04-29
AU2002334641B2 (en)	2007-03-29
ATE356126T1 (de)	2007-03-15
DK1427732T3 (da)	2006-10-30
CN1555379A (zh)	2004-12-15
DE60202782T2 (de)	2006-01-19
CA2461072A1 (en)	2003-03-27
AR037502A1 (es)	2004-11-17
CO5560590A2 (es)	2005-09-30
PL370362A1 (en)	2005-05-16
AR037145A1 (es)	2004-10-27
NO20041594L (no)	2004-06-21
CO5560589A2 (es)	2005-09-30
ZA200401402B (en)	2004-08-27
CO5560579A2 (es)	2005-09-30
WO2003024973A1 (en)	2003-03-27
WO2003024971A1 (en)	2003-03-27
MA27064A1 (fr)	2004-12-20
NO20041605L (no)	2004-06-21
KR20040035835A (ko)	2004-04-29
BR0212673A (pt)	2004-08-24
US6566357B1 (en)	2003-05-20
SA03230529B1 (ar)	2008-06-21
DE60213108T2 (de)	2007-02-08
DE60213108D1 (de)	2006-08-24
DE60218704D1 (de)	2007-04-19
CZ2004358A3 (cs)	2004-07-14
HUP0402378A3 (en)	2008-10-28
PE20030430A1 (es)	2003-06-24
JP2005504083A (ja)	2005-02-10
RU2004111803A (ru)	2005-10-10
MY129329A (en)	2007-03-30
CA2461073A1 (en)	2003-03-27
EP1427728A1 (en)	2004-06-16
MY129069A (en)	2007-03-30
CZ2004345A3 (cs)	2004-06-16
JP2005504082A (ja)	2005-02-10
RU2278864C2 (ru)	2006-06-27
EG24413A (en)	2009-05-25
CA2461071A1 (en)	2003-03-27
MXPA04002574A (es)	2004-06-18
IL160682A0 (en)	2004-08-31
ES2237691T3 (es)	2005-08-01
AR037237A1 (es)	2004-11-03
CN1249066C (zh)	2006-04-05
MA27065A1 (fr)	2004-12-20
DE60202782D1 (de)	2005-03-03
US20030105084A1 (en)	2003-06-05
ATE332901T1 (de)	2006-08-15
NZ531063A (en)	2007-08-31
PT1427727E (pt)	2005-06-30
SK1482004A3 (en)	2004-08-03
PE20030446A1 (es)	2003-07-21
IL160741A0 (en)	2004-08-31
EP1427728B1 (en)	2007-03-07
PL370351A1 (en)	2005-05-16
NZ531123A (en)	2006-08-31
HK1071565A1 (en)	2005-07-22
HUP0500752A2 (en)	2006-01-30
MXPA04002569A (es)	2004-05-31

Publication	Publication Date	Title
SK1502004A3 (en)	2004-09-08	6,7-Dihydro-5H-pyrazolo[1,2-a] pyrazol-1-ones regulating inflammatory cytokines
AU2002327690A1 (en)	2003-06-05	6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
KR20080002865A (ko)	2008-01-04	피리도[２,３-ｄ]피리미딘-７-온 및３,４-디히드로피리미도[４,５-ｄ]피리미딘-２(１ｈ)-온유도체의 제조 방법
US6730668B2 (en)	2004-05-04	6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US6849627B2 (en)	2005-02-01	6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7326714B2 (en)	2008-02-05	6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US20040087639A1 (en)	2004-05-06	6,7-Dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia